269 related articles for article (PubMed ID: 26962218)
21. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.
Clements JE; Montelaro RC; Zink MC; Amedee AM; Miller S; Trichel AM; Jagerski B; Hauer D; Martin LN; Bohm RP
J Virol; 1995 May; 69(5):2737-44. PubMed ID: 7707496
[TBL] [Abstract][Full Text] [Related]
22. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys.
Walther-Jallow L; Nilsson C; Söderlund J; Ten Haaft P; Mäkitalo B; Biberfeld P; Böttiger P; Heeney J; Biberfeld G; Thorstensson R
J Gen Virol; 2001 Jul; 82(Pt 7):1601-1612. PubMed ID: 11413371
[TBL] [Abstract][Full Text] [Related]
23. Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE.
Pinczewski J; Zhao J; Malkevitch N; Patterson LJ; Aldrich K; Alvord WG; Robert-Guroff M
Viral Immunol; 2005; 18(1):236-43. PubMed ID: 15802969
[TBL] [Abstract][Full Text] [Related]
24. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions.
Wang SW; Kozlowski PA; Schmelz G; Manson K; Wyand MS; Glickman R; Montefiori D; Lifson JD; Johnson RP; Neutra MR; Aldovini A
J Virol; 2000 Nov; 74(22):10514-22. PubMed ID: 11044096
[TBL] [Abstract][Full Text] [Related]
25. Recombinant Herpesvirus Vectors: Durable Immune Responses and Durable Protection against Simian Immunodeficiency Virus SIVmac239 Acquisition.
Castro IM; Ricciardi MJ; Gonzalez-Nieto L; Rakasz EG; Lifson JD; Desrosiers RC; Watkins DI; Martins MA
J Virol; 2021 Jun; 95(14):e0033021. PubMed ID: 33910957
[TBL] [Abstract][Full Text] [Related]
26. Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.
Vagenas P; Williams VG; Piatak M; Bess JW; Lifson JD; Blanchard JL; Gettie A; Robbiani M
J Acquir Immune Defic Syndr; 2009 Dec; 52(4):433-42. PubMed ID: 19779309
[TBL] [Abstract][Full Text] [Related]
27. Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys.
Sun C; Chen Z; Tang X; Zhang Y; Feng L; Du Y; Xiao L; Liu L; Zhu W; Chen L; Zhang L
J Virol; 2013 May; 87(10):5669-77. PubMed ID: 23487457
[TBL] [Abstract][Full Text] [Related]
28. A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.
Amara RR; Patel K; Niedziela G; Nigam P; Sharma S; Staprans SI; Montefiori DC; Chenareddi L; Herndon JG; Robinson HL; McClure HM; Novembre FJ
J Virol; 2005 Dec; 79(24):15356-67. PubMed ID: 16306607
[TBL] [Abstract][Full Text] [Related]
29. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses.
Malkevitch NV; Patterson LJ; Aldrich MK; Wu Y; Venzon D; Florese RH; Kalyanaraman VS; Pal R; Lee EM; Zhao J; Cristillo A; Robert-Guroff M
Virology; 2006 Sep; 353(1):83-98. PubMed ID: 16814356
[TBL] [Abstract][Full Text] [Related]
30. Live attenuated SIV vaccines are not effective in a postexposure vaccination model.
Linhart H; Gundlach BR; Sopper S; Dittmer U; Mätz-Rensing K; Kuhn EM; Müller J; Hunsmann G; Stahl-Hennig C; Uberla K
AIDS Res Hum Retroviruses; 1997 May; 13(7):593-9. PubMed ID: 9135877
[TBL] [Abstract][Full Text] [Related]
31. In vivo resistance to simian immunodeficiency virus superinfection depends on attenuated virus dose.
Cranage MP; Sharpe SA; Whatmore AM; Polyanskaya N; Norley S; Cook N; Leech S; Dennis MJ; Hall GA
J Gen Virol; 1998 Aug; 79 ( Pt 8)():1935-44. PubMed ID: 9714241
[TBL] [Abstract][Full Text] [Related]
32. Live attenuated simian immunodeficiency virus vaccination confers superinfection resistance against macrophage-tropic and neurovirulent wild-type SIV challenge.
Berry N; Ham C; Alden J; Clarke S; Stebbings R; Stott J; Ferguson D; Almond N
J Gen Virol; 2015 Jul; 96(Pt 7):1918-29. PubMed ID: 25834093
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge.
Busch M; Abel K; Li J; Piatak M; Lifson JD; Miller CJ
Vaccine; 2005 Jul; 23(31):4036-47. PubMed ID: 15963361
[TBL] [Abstract][Full Text] [Related]
34. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
[TBL] [Abstract][Full Text] [Related]
35. Live simian immunodeficiency virus vaccine correlate of protection: immune complex-inhibitory Fc receptor interactions that reduce target cell availability.
Smith AJ; Wietgrefe SW; Shang L; Reilly CS; Southern PJ; Perkey KE; Duan L; Kohler H; Müller S; Robinson J; Carlis JV; Li Q; Johnson RP; Haase AT
J Immunol; 2014 Sep; 193(6):3126-33. PubMed ID: 25143442
[TBL] [Abstract][Full Text] [Related]
36. Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.
Willer DO; Guan Y; Luscher MA; Li B; Pilon R; Fournier J; Parenteau M; Wainberg MA; Sandstrom P; MacDonald KS
J Virol; 2010 Mar; 84(5):2304-17. PubMed ID: 20032177
[TBL] [Abstract][Full Text] [Related]
37. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.
Lewis MG; Yalley-Ogunro J; Greenhouse JJ; Brennan TP; Jiang JB; VanCott TC; Lu Y; Eddy GA; Birx DL
J Virol; 1999 Feb; 73(2):1262-70. PubMed ID: 9882330
[TBL] [Abstract][Full Text] [Related]
38. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.
Alpert MD; Harvey JD; Lauer WA; Reeves RK; Piatak M; Carville A; Mansfield KG; Lifson JD; Li W; Desrosiers RC; Johnson RP; Evans DT
PLoS Pathog; 2012; 8(8):e1002890. PubMed ID: 22927823
[TBL] [Abstract][Full Text] [Related]
39. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
Cole KS; Rowles JL; Jagerski BA; Murphey-Corb M; Unangst T; Clements JE; Robinson J; Wyand MS; Desrosiers RC; Montelaro RC
J Virol; 1997 Jul; 71(7):5069-79. PubMed ID: 9188572
[TBL] [Abstract][Full Text] [Related]
40. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus.
Tenner-Racz K; Stahl Hennig C; Uberla K; Stoiber H; Ignatius R; Heeney J; Steinman RM; Racz P
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3017-22. PubMed ID: 14970317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
